NDAORALTABLETPriority Review
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIKAFTA is a triple-combination oral tablet containing elexacaftor, tezacaftor, and ivacaftor approved in October 2019 for cystic fibrosis patients with specific CFTR mutations. It represents a major advance in CF treatment by targeting the underlying cause of the disease through CFTR modulation. This copackaged formulation combines three complementary mechanisms to improve CFTR protein function and trafficking.
Peak12.2 years to LOE
At peak lifecycle stage with substantial market penetration in CF, the brand team likely maintains robust size focused on market maintenance and patient support infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations
Started Nov 2016
2 enrolled
Cystic Fibrosis
Career Relevance
TRIKAFTA represents a high-value, mission-driven therapeutic area in rare disease with long-term career stability through 2038. Professionals on this team benefit from working on a transformative CF therapy with deep patient relationships and substantial commercial resources behind a market-leading product.
Brand Manager
Worked on TRIKAFTA (COPACKAGED) at Vertex Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.